Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
25 juil. 2024 05h00 HE
|
Kaerus Bioscience
LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of...
NeuroQure Acquires Patents to Detect Autism in Newborns with a Skin Sample
13 déc. 2023 09h30 HE
|
NeuroQure
IRVINE, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- NeuroQure, a pioneering biotech startup specializing in gene therapy for neurocognitive disorders, has reached a pivotal milestone in the...
Quris Closes $28 Million in Seed Funding From Top Institutional Investors
11 janv. 2022 14h45 HE
|
Quris Technologies
BOSTON and TEL-AVIV, Israel, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Quris, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced the final close of $28 million in...
Quris Closes Critical Drug Development Gaps With New Clinical Prediction AI Platform
18 oct. 2021 07h30 HE
|
Quris Technologies
BOSTON and TEL-AVIV, Israel, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Quris, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today launched the first clinical prediction AI...
Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers
03 mars 2020 12h07 HE
|
Zynerba Pharmaceuticals, Inc.
- Data Presented at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Meeting - - Health State Utility Index Data Estimate the Significant Health Burden of FXS, and Suggest the...
Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel™ in Fragile X Syndrome
26 févr. 2020 06h50 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
08 mai 2019 06h50 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., May 08, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel™ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)
06 mai 2019 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
- Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs - - Enrollment Progressing in Pivotal CONNECT-FX Trial of Zygel in FXS, with Data Expected...
Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Cannabidiol
26 févr. 2019 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome
12 juil. 2018 07h30 HE
|
Zynerba Pharmaceuticals, Inc.
- Significant Improvements in Behavioral Symptoms Observed in Patients and Sustained through 38 Weeks of Treatment with ZYN002 -- Presentation Today at the 16th NFXF International Fragile X Conference...